<DOC>
	<DOCNO>NCT01405339</DOCNO>
	<brief_summary>Budesonide , steroid subtype , use adjunctive treatment chronic rhinosinusitis topical nasal steroid spray . The current standard care St. Paul 's Sinus Centre administer budesonide via Mucosal Atomization Device ( MAD ) . It believe MAD good device standard nasal lavage fine mist enhances absorption improve bioavailability . No study do determine enhance absorption improve bioavailability budesonide via MAD could potentially affect hypothalamic-pituitary-adrenal ( HPA ) axis , result suppression body 's production natural steroid .</brief_summary>
	<brief_title>Budesonide Application Via Mucosal Atomization Device Treatment Chronic Rhinosinusitis When Utilized Topical Nasal Steroid Spray</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>19 year age old Diagnosed CRS without polyp Awaiting Functional Endoscopic Sinus Surgery Give consent Concurrent recent use ( within past 30 day ) systemic corticosteroid History pituitary disease Morbid obesity ( body mass index [ calculate weight kilogram divide height meter square ] Concurrent recent use medication accelerate clearance cortisol : Such dilantin , rifampin , amphetamine , lithium carbonate Concurrent use medication interfere production cortisol : Such ketoconazole , amphotericin B , bupropion , Echinacea , fluoroquinolones , itraconazole , licorice Use oral contraception Use female male hormone therapy Known hypersensitivity cortisol , corticotropin , cosyntropin</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>